Recombinant γ-interferon as first line therapy for high risk myelodysplastic syndromes

Anna T. Maiolo, Agostino Cortelezzi, Rossella Calori, Elio E. Polli

Research output: Contribution to journalArticlepeer-review


Thirty patients affected by previously untreated high risk myelodysplastic syndromes (MDS) were treated with human recombinant γ-interferon (r-IFN-γ): 15 of them with a higher dose (HD) of 0.1 mg/sqm, three times a week and 15 with a lower dose (LD) of 0.01 mg/sqm, three times a week, both doses administered subcutaneously (s.o.). The therapy was fairly well tolerated and few major toxic events were documented. Sustained improvement of one or more clinico-hematologic parameters was observed in 43.3% of the patients (26.6% and 60.0% for the lower and higher dose, respectively). Median survival time from the start of IFN-γ therapy was 15+ months (range: 1-26) for patients with refractory anemia with excess of blasts (RAEB) versus 5 months (range 2-12) for patients with RAEB in transformation (RAEB-t); 15+ months (range 1-26) for HD patients versus 8 months (range 2-23) for patients treated with LD regimen; 16+ months (range 9-26) for responders versus 7 months (range 1-22) for nonresponders. All these three variables (diagnosis, treatment, and response to treatment) turned out to be statistically significant (p = at least

Original languageEnglish
Pages (from-to)480-485
Number of pages6
Issue number7
Publication statusPublished - Jul 1990

ASJC Scopus subject areas

  • Hematology
  • Cancer Research


Dive into the research topics of 'Recombinant γ-interferon as first line therapy for high risk myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this